Market openNon-fractional

KalVista Pharmaceuticals/KALV

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About KalVista Pharmaceuticals

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

Ticker

KALV

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

150

KALV Metrics

BasicAdvanced
$647M
Market cap
-
P/E ratio
-$3.44
EPS
0.91
Beta
-
Dividend rate
$647M
0.91
9.896
9.702
2.912
3.542
-41.94%
-68.90%
3.1
3.1
-6.211
3.35%
12.44%

What the Analysts think about KALV

Analyst Ratings

Majority rating from 6 analysts.
Buy

KALV Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$0
NaN%
Net income
-$29M
5.07%
Profit margin
0.00%
NaN%

KALV Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 9.49%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
-$0.77
-$0.74
-$0.80
-$0.84
-
Expected
-$0.94
-$0.86
-$0.79
-$0.77
-$0.73
Surprise
-17.94%
-13.79%
1.73%
9.49%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for KalVista Pharmaceuticals stock?

KalVista Pharmaceuticals (KALV) has a market cap of $647M as of July 23, 2024.

What is the P/E ratio for KalVista Pharmaceuticals stock?

The price to earnings (P/E) ratio for KalVista Pharmaceuticals (KALV) stock is 0 as of July 23, 2024.

Does KalVista Pharmaceuticals stock pay dividends?

No, KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next KalVista Pharmaceuticals dividend payment date?

KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders.

What is the beta indicator for KalVista Pharmaceuticals?

KalVista Pharmaceuticals (KALV) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell KalVista Pharmaceuticals stock

Buy or sell KalVista Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing